Drug and medicinal products for the consumer. a critical evaluation
Rüsing, D.; Bauer, K.; Verspohl, E.J.
Medizinische Monatsschrift für Pharmazeuten 27(3): 84-91
2004
ISSN/ISBN: 0342-9601 PMID: 15032251 Document Number: 579114
Document emailed within 1 workday
Related Documents
Ruys-Dudok van Heel, I.; Cohen, A.F.; Wit, J.M.; van der Heijden, A.J.; van den Anker, J.N.; van Meurs, A.H. 1998: Clinical drug research in children: current international guidelines. Committee for Proprietary Medicinal Products Nederlands Tijdschrift Voor Geneeskunde 142(1): 6-9Joung, J.; Robertson, J.S.; Griffiths, E.; Knezevic, I.; Bristow, A.; Gray, E.; Thorpe, R.; Robertson, J.S.; Cheraghali, M.; Castanheira, L.Gomes.; de Oliveira, G.Garcia.; Griffiths, E.; Nyarko, K.; Kalinke, U.; Kawanishi, T.; Yamaguchi, T.; Krayenbühl, J.Christian.; Schmid-Appert, M.; Poulis, M.; Schellekens, H.; Sohn, Y.; Southern, J.; Webber, K.; Weise, M.; Gogoi, S.Parthajyoti.; Junzhi, W.; Richardson, P.; Gairola, S.; Mascaro, J.; Fox, A.; Krause, R.; Schiestl, M.; Kox, S.; Eshkol, A.; Mattavelli, R.Balocco.; Lasseur, S.; Dong, J-Cui.; Wood, D.; Knezevic, I.; Joun 2008: WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007 Biologicals: journal of the International Association of Biological Standardization 36(4): 269-276
Hakkinen, P.J.; Kelling, C.K.; Callender, J.C. 1991: Exposure assessment of consumer products: human body weights and total body surface areas to use, and sources of data for specific products Veterinary and Human Toxicology 33(1): 61-65
Ward, T.S.; Jablonski, H.I.; Vanantwerp, J. 1992: Drug use evaluation of acetaminophen-containing products at a community hospital Hospital Formulary 27(9): 947
Kurlberg, P.A.; Blomgren, P. 1992: Market research surveys in the marketing of consumer products Acta Dermato-Venereologica. Supplementum 177: 47-52
Hubinger, J.C. 2010: A survey of phthalate esters in consumer cosmetic products Journal of Cosmetic Science 61(6): 457-465
Kes, P.; Mesar, I.; Bašić-Jukić, N.; Rački, S. 2014: What doctors need to know about biosimilar medicinal products? Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 68(2): 201-205
Ernst, E. 2004: Risks of herbal medicinal products Pharmacoepidemiology and Drug Safety 13(11): 767-771
Nonyelum, S.C.; Nkem, N.; Ifeyinwa, C.-N.; Orisakwe, O.E. 2010: Safety warnings and first aid instructions on consumer and pharmaceutical products in Nigeria: has there been an improvement? JPMA. Journal of the Pakistan Medical Association 60(10): 801-804
Hubinger, J.C. 2009: Determination of retinol, retinyl palmitate, and retinoic acid in consumer cosmetic products Journal of Cosmetic Science 60(5): 485-500
Ali, M. 2010: A novel method of characterizing medicinal drug aerosols generated from pulmonary drug delivery devices PDA Journal of Pharmaceutical Science and Technology 64(4): 364-372
Marimbert, J. 2005: Sanitary risk: medicinal products and medical devices La Revue du Praticien 55(18): 2026-2032
Kaye, S.; Ortiz, T.; Miranda Massari, J.R.; González, M.J. 2003: Adverse effects and interactions of medicinal herbal products Boletin de la Asociacion Medica de Puerto Rico 95(6): 32-36; 40-41
Bass, R.; Ulbrich, B.; Hildebrandt, A.G.; Weissinger, J.; Doi, O.; Baeder, C.; Fumero, S.; Harada, Y.; Lehmann, H.; Manson, J. 1991: Draft guideline on detection of toxicity to reproduction for medicinal products Adverse Drug Reactions and Toxicological Reviews 10(3): 127-141
Wiatrzyk, A.; Polak, M.; Czajka, U.; Krysztopa-Grzybowska, K.; Lutyńska, A. 2013: Phenotypic and genotypic characterization of probiotic bacterial strains used in medicinal products Medycyna Doswiadczalna i Mikrobiologia 65(1): 47-56
Kalny, P.; Wyderska, S.; Fijałek, Z.; Wroczyński, P. 2012: Determination of selected elements in different pharmaceutical forms of some Polish herbal medicinal products Acta Poloniae Pharmaceutica 69(2): 279-283
Elferink, A.J.; Toivonen, M.; van Bronswijk, H. 1999: Safety and efficacy of vigabatrin and carbamazepine. CPMP. The Committee for Proprietary Medicinal Products Lancet 354(9187): 1387-1388
Vos, E.J.; Huitema, A.D.R. 2006: Defining trials of medicinal products according to the revised Dutch Medical Research in Human Subjects Act (WMO) Nederlands Tijdschrift Voor Geneeskunde 150(38): 2104-2107
Zmudzki, J. 2003: Risk analysis rules for the establishing of maximum residue limits of veterinary medicinal products Roczniki Panstwowego Zakladu Higieny 54 Suppl: 12-13
Brodniewicz-Proba, T. 2008: The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products Acta Poloniae Pharmaceutica 65(6): 641-645